New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma

Autor: Kaylee J. Smith, Sunitha Nagrath, Eric Lin, Christopher Leu, Diane M. Simeone, G-Su Park, Neehar D. Parikh, Theodore H. Welling, Shanshan Wan, Tae Hyun Kim, John Steffes, Ning Kuo, Thomas Plegue, Nataliya Razimulava, Ryan Delaney, Hui Guo
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Hepatocellular carcinoma
Embolism
Microfluidics
lcsh:Medicine
Metastasis
Translational Research
Biomedical
0302 clinical medicine
Circulating tumor cell
Lab-On-A-Chip Devices
Neoplasm Metastasis
lcsh:Science
Aged
80 and over
education.field_of_study
Multidisciplinary
biology
Liver Neoplasms
Hep G2 Cells
Middle Aged
Neoplastic Cells
Circulating
Treatment Outcome
030220 oncology & carcinogenesis
Disease Progression
Neoplastic Stem Cells
Carcinoma
Hepatocellular
Population
Article
03 medical and health sciences
Cancer stem cell
Biomarkers
Tumor
Carcinoma
medicine
Humans
education
neoplasms
Aged
business.industry
CD44
lcsh:R
Translational research
medicine.disease
digestive system diseases
030104 developmental biology
Microscopy
Fluorescence
Drug Resistance
Neoplasm
Tumor progression
biology.protein
Cancer research
lcsh:Q
Neoplasm Recurrence
Local
business
Zdroj: Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports
ISSN: 2045-2322
DOI: 10.1038/s41598-019-54960-y
Popis: Hepatocellular Carcinoma (HCC) is one of the most lethal cancers with a high mortality and recurrence rate. Circulating tumor cell (CTC) detection offers various opportunities to advance early detection and monitoring of HCC tumors which is crucial for improving patient outcome. We developed and optimized a novel Labyrinth microfluidic device to efficiently isolate CTCs from peripheral blood of HCC patients. CTCs were identified in 88.1% of the HCC patients over different tumor stages. The CTC positivity rate was significantly higher in patients with more advanced HCC stages. In addition, 71.4% of the HCC patients demonstrated CTCs positive for cancer stem cell marker, CD44, suggesting that the major population of CTCs could possess stemness properties to facilitate tumor cell survival and dissemination. Furthermore, 55% of the patients had the presence of circulating tumor microemboli (CTM) which also correlated with advanced HCC stage, indicating the association of CTM with tumor progression. Our results show effective CTC capture from HCC patients, presenting a new method for future noninvasive screening and surveillance strategies. Importantly, the detection of CTCs with stemness markers and CTM provides unique insights into the biology of CTCs and their mechanisms influencing metastasis, recurrence and therapeutic resistance.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje